The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
SAN FRANCISCO (Reuters) - The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
The UnitedHealth Group is overcharging patients for necessary life-saving drugs as a result of price gouging that increases ...
Newer entrants to the pharmacy benefit management market will continue to face stiff competition in 2025 as they seek more ...
The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...